Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Leuk Lymphoma. 2013 Jul;54(7):1442-9. doi: 10.3109/10428194.2012.743656. Epub 2012 Nov 26.
PRAME and WT1 transcript levels were simultaneously measured in 312 bone marrow samples collected from patients with newly diagnosed myelodysplastic syndromes (MDS) and 111 samples collected during the treatment of 17 patients. Both the positive rate and the > 1-log increase expression frequency of PRAME were similar to those of WT1 (74.4 % vs. 77.6%; 51.6% vs. 49.0%), and 88.1% of patients overexpressed at least one marker. Moreover, the frequencies of PRAME expression with higher degrees of increase were significantly higher compared with those of WT1 expression (> 2-log increase: 30.8% vs. 3.8%; > 3-log increase: 9.0% vs. 0%; all p < 0.001). PRAME had a higher log increase than WT1 in 53.3% of the patients with overexpressed WT1. Both PRAME and WT1 transcript levels generally fluctuated within the normal range after hematopoietic stem cell transplant in all 10 patients in continuous complete remission. Six out of seven patients were predicted relapse by the combined detection: sustained positivity, or significant increase to be positive for both WT1 and PRAME in three patients, earlier by PRAME than WT1 or by PRAME alone in three patients. Thus, PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in MDS.
在 312 例新诊断的骨髓增生异常综合征（MDS）患者的骨髓样本和 17 例患者治疗过程中的 111 例样本中，同时测量了 PRAME 和 WT1 的转录水平。PRAME 的阳性率和 > 1 倍表达频率与 WT1 相似（74.4%比 77.6%；51.6%比 49.0%），88.1%的患者至少表达一种标志物。此外，PRAME 表达增加程度较高的频率明显高于 WT1 表达（> 2 倍增加：30.8%比 3.8%；> 3 倍增加：9.0%比 0%；均 P < 0.001）。在 WT1 过度表达的患者中，有 53.3%的患者 PRAME 的对数增加高于 WT1。在所有 10 例连续完全缓解的造血干细胞移植后，PRAME 和 WT1 转录本水平通常在正常范围内波动。在 7 例患者中，有 6 例通过联合检测预测复发：3 例患者持续阳性，或 WT1 和 PRAME 均显著增加为阳性，3 例患者 PRAME 早于 WT1 或仅 PRAME 阳性。因此，PRAME 和 WT1 转录本构成了 MDS 微小残留病监测的良好分子标志物组合。
